Dr. Bruce Roser, MB BS, PhD, Chairman and co-founder of Stablepharma, is retiring, leaving behind a remarkable legacy in the field of fridge-free vaccines and pharmaceuticals.
Through his tireless efforts to validate the science behind this ground-breaking technology, which culminated in Stablepharma’s technology platform StablevaX™, Dr. Roser has made a significant contribution to the future of global healthcare outcomes by his vision of making vital medications more accessible. “For the first time in half a century of trying, I am closer to realising my dream of making safe, stable drugs and vaccines available to the whole world, rich and poor, no matter where they live”, said Dr. Roser.
Stablepharma’s technology platform, StablevaX™ has the ability to convert biopharmaceuticals, vaccines and diagnostic products into fridge-free forms that do not require refrigeration at any point, during manufacture, distribution or storage. This innovative technology greatly extends the shelf life of the products, reduces the current reliance on the global cold chain, thereby reducing CO2 emissions associated with packaging and refrigeration.
Under the Chairmanship of Dr. Roser, the scientific and commercial teams have expanded in Madrid and London, transforming Stablepharma from a promising startup with revolutionary technology, to an important player within the biopharma sector, capable of seriously impacting the world of vaccines and pharmaceuticals.
“The time for fundamental research is passing and we are moving smoothly into production, with the introduction of a new generation of room temperature vaccines and drugs that can be safely and indefinitely stored on the shelf, anywhere on earth”. “This is deeply gratifying to me, and I can now confidently retire, knowing that we have the best team in place to drive forward our vision”. “I wish to express my sincere thanks to Nick Child, SVP & Co Founder of Stablepharma and Ozgur Tuncer, CEO & Executive Director”.
Özgür Tuncer, CEO commented, “Bruce’s dedication to and perseverance in developing fridge-free vaccines and drugs has paved the way for innovative solutions in healthcare for the world but particularly in resource-limited settings. His commitment to advancing medical science will be remembered and celebrated by all of the Stablepharma team for years to come”.
Stablepharma has a pipeline of thermostable vaccines and technologies that have progressed from early research into full development, including SPVX02, an adult booster vaccine for the prevention of Tetanus & Diphtheria (Td), SPVX06, a vaccine for the prevention of Tetanus (TT) and Thermostable RNA-LNP based vaccines. These projects align with Stablepharma’s commitment to positively impact global health and we continue to expand our portfolio through partnerships with other European vaccine manufacturers.
“It is with mixed emotions that I congratulate Bruce on his well-earned retirement, it has been an honour to work with him and be exposed to his brilliant scientific mind over the years”, said Nick Child. “Stablepharma is on the cusp of some important manufacturing and commercial milestones, and much of this is thanks to Dr. Roser’s scientific expertise”.
Stablepharma will shortly announce their new Chairman who takes up the role in November 2024.